ADPT (Adaptive Biotechnologies) Book Value per Share: $1.36 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADPT Adaptive Biotechnologies Corp ADPT
68 GF Score
Price $21.02
GF Value $10.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Book Value per Share?

Adaptive Biotechnologies ADPT -0.19% 68 Book Value per Share is $1.36 as of Mar. 2026. GuruFocus rates ADPT with a GF Score™ of 68/100 and a GF Value™ of $10.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Adaptive Biotechnologies's book value per share for the quarter that ended in Mar. 2026 was $1.36.

During the past 12 months, Adaptive Biotechnologies's average Book Value Per Share Growth Rate was 8.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -24.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -25.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Adaptive Biotechnologies was -10.70% per year. The lowest was -31.50% per year. And the median was -25.35% per year.

Adaptive Biotechnologies's current price is $21.02. Its book value per share for the quarter that ended in Mar. 2026 was $1.36. Hence, today's PB Ratio of Adaptive Biotechnologies is 15.51.

During the past 9 years, the highest P/B Ratio of Adaptive Biotechnologies was 20.29. The lowest was 1.29. And the median was 5.92.

Warning Sign:

Adaptive Biotechnologies Corp stock PB Ratio (=15.54) is close to 5-year high of 15.64.


Adaptive Biotechnologies  (NAS:ADPT) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Adaptive Biotechnologies Book Value per Share Related Terms


Adaptive Biotechnologies Book Value per Share Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Book Value per Share Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Book Value per Share
Get a 7-Day Free Trial Premium Member Only 4.27 3.24 2.13 1.37 1.42

Adaptive Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 1.18 1.34 1.42 1.36

ADPT vs GRAL, WGS, RDNT: Book Value per Share Comparison

For the Diagnostics & Research subindustry, Adaptive Biotechnologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's PB Ratio distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's PB Ratio falls into.


ADPT
68GF Score
Adaptive Biotechnologies Corp ADPT
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies Book Value per Share Calculation

Adaptive Biotechnologies's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(218.8-0.0)/153.8
=1.42

Adaptive Biotechnologies's Book Value Per Share for the quarter that ended in Mar. 2026 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(216.3-0.0)/159.7
=1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $1.36 mean?
Adaptive Biotechnologies (ADPT) has a Book Value per Share of $1.36 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Adaptive Biotechnologies and its competitors.
Is Adaptive Biotechnologies' Book Value per Share too high?
Adaptive Biotechnologies' current Book Value per Share is $1.36. Overall, Adaptive Biotechnologies has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Book Value per Share compare to GRAL and WGS?
Adaptive Biotechnologies' Book Value per Share of $1.36 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Medical Diagnostics & Research company?
A good Book Value per Share depends on the Medical Diagnostics & Research industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Book Value per Share is $1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.05, compared to a current price of $21.02 — trading 109.2% above its estimated fair value. The current Book Value per Share is $1.36. Adaptive Biotechnologies' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Book Value per Share is $1.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $21.02 is trading 109.2% above its estimated GF Value™ of $10.05. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Book Value per Share: $1.36
  • GF Value™: $10.05 vs. price of $21.02 (109.2% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
68GF Score

Get the complete analysis for ADPT

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.02
Price
$10.05
GF Value